SGLT2 Inhibitors and the Risk of Venous Thromboembolism: A Population-based Cohort Study.
Stephanie AloeChristopher FilliterShahrzad SalmasiSamuel IgweokpalaOriana H Y YuVicky TagalakisKristian B FilionPublished in: British journal of clinical pharmacology (2023)
We found that SGLT2Is were not associated with an increased risk of VTE compared to DPP-4Is. Although we observed a numerically decreased risk of VTE with SGLT2Is, estimates were accompanied by wide 95% CIs. Nonetheless, given the morbidity associated with VTE, our results provide some reassurance regarding the safety of SGLT2Is with respect to VTE.